Tilavonemab (ABBV-8E12) was an anti-tau monoclonal antibody developed by AbbVie targeting extracellular tau aggregates. It was tested in a Phase 2 randomized, placebo-controlled trial in patients with progressive supranuclear palsy (PSP), representing one of the most rigorous tests of anti-tau antibody therapy in a canonical 4R tauopathy. The trial failed to meet its primary efficacy endpoints, providing critical lessons for the entire anti-tau therapeutic field.
The Phase 2 trial was a randomized, double-blind, placebo-controlled study enrolling patients with clinically diagnosed PSP. Key design elements included:
- Population: Patients meeting probable PSP criteria (Richardson syndrome or PSP-parkinsonism subtypes)
- Randomization: 2:1 active to placebo ratio
- Dosing: Intravenous infusions of tilavonemab at specified doses
- Duration: 52-week treatment period with follow-up
- Primary Endpoints: Change from baseline in PSP-Rating Scale (PSPRS) score
- Secondary Endpoints: Clinical measures including cognitive assessments, functional scales, and biomarker endpoints
Tilavonemab was designed to bind to extracellular tau species, based on the hypothesis that neutralizing extracellular tau could:
- Block intercellular propagation of tau pathology
- Reduce synaptic tau transfer
- Modulate the extracellular tau pool detected in cerebrospinal fluid (CSF)
The antibody targeted the N-terminal region of tau, similar to other failed anti-tau antibodies including gosuranemab (BIIB092) and zagotenemab (LY3303560).
The trial failed to demonstrate statistical significance on the primary endpoint (change in PSPRS score). Key findings included:
- No significant difference in clinical progression between treatment and placebo groups
- Substantial variability in treatment response across participants
- Both groups showed expected disease progression over the 52-week period
The biomarker data revealed a critical disconnect between target engagement and clinical efficacy:
- The antibody achieved reductions in CSF tau species, demonstrating target engagement
- However, clinical progression continued despite biomarker modulation
- This disconnect suggested that N-terminal tau fragments may not be the primary drivers of neurodegeneration in PSP
Tilavonemab showed an acceptable safety profile consistent with other anti-tau antibodies:
- No unexpected serious adverse events
- Infusion-related reactions were manageable
- The safety profile did not limit dose escalation
The fundamental issue with tilavonemab and other first-generation anti-tau antibodies was the choice of epitope:
- N-terminal targeting assumed that N-terminal tau fragments mediate intercellular transfer and pathology spread
- However, evidence emerged that the most pathogenic tau species are mid-domain and C-terminal aggregates that seed intracellular oligomers and fibrils
- The disconnect between biomarker engagement (CSF tau reduction) and clinical efficacy suggests N-terminal fragments are "downstream" rather than "upstream" drivers of neurodegeneration
Anti-tau antibodies face a fundamental biological barrier:
- Antibodies do not efficiently cross the blood-brain barrier
- Even with peripheral targeting, intracellular tau pools (where pathology originates and accumulates) are inaccessible
- PSP involves intracellular 4R tau aggregation in neurons and glia — extracellular antibodies cannot directly neutralize the primary pathogenic species
The trial enrolled patients with established PSP:
- Mean disease duration at enrollment was several years
- Substantial neuronal loss and tau pathology burden already present
- Treatment may need to begin in prodromal or pre-symptomatic stages to prevent irreversible damage
- The "downstream" nature of the pathology means intervention at the symptomatic stage may be too late
PSP presents specific trial design challenges:
- Rapid progression: PSP progresses rapidly, creating high background noise
- Phenotypic variability: Different PSP subtypes have variable rates of decline
- Outcome measure sensitivity: PSPRS may not capture subtle treatment effects
- Small sample sizes: PSP is relatively rare, limiting statistical power
- Floor/ceiling effects: Advanced patients may not show measurable decline
Tilavonemab was not alone — multiple anti-tau antibodies targeting N-terminal epitopes failed:
| Antibody |
Company |
Target |
Indication |
Outcome |
| Gosuranemab (BIIB092) |
Bristol-Myers Squibb |
N-terminal tau |
PSP, AD |
Failed |
| Tilavonemab (ABBV-8E12) |
AbbVie |
N-terminal tau |
PSP, AD |
Failed |
| Zagotenemab (LY3303560) |
Eli Lilly |
N-terminal conformational |
AD |
Discontinued |
| Semorinemab (RG6100) |
Roche |
Mid-region tau |
AD |
Failed |
This pattern suggests a class-level problem with the N-terminal targeting strategy rather than molecule-specific failures.
Future programs should prioritize:
- Mid-domain and C-terminal epitopes that target aggregation-prone regions
- Conformational epitopes that recognize pathological tau conformers
- Antibodies with demonstrated binding to disease-relevant tau species (e.g., oligomers, seeding-competent species)
The field is shifting toward:
- Prodromal or pre-symptomatic intervention
- Biomarker-enriched populations with evidence of active pathology
- Younger patients with less established neurodegeneration
Novel approaches to improve brain exposure:
- Antibody engineering for enhanced blood-brain barrier penetration
- Transport vehicle (TV) technology
- Bispecific antibodies designed for CNS uptake
More sophisticated biomarker strategies:
- Tau PET for CNS target engagement confirmation
- Fluid biomarkers (CSF and plasma p-tau species) for patient selection
- Pharmacodynamic markers to confirm mechanism activation
Given the complexity of tau pathology:
- Targeting multiple nodes in the tau lifecycle (aggregation, propagation, clearance)
- Combination with neuroprotective or disease-modifying approaches
- Platform trials testing multiple hypotheses simultaneously